EdRip in CHF 18m OncoEthix series-B round

SV Life Sciences has also joined existing investors Index Ventures and Endeavour Vision in the round.

EdRip invested from the vehicle BioDiscovery 4, which held a first close on €125m in July 2012. The investor's fourth life sciences fund has a €200m target.

The fresh capital will underpin the clinical development of the firm's lead product – an oncology drug.

Previous funding
In August 2009, Index led a CHF 3.7m series-A round alongside Endeavour Vision.

Company
Founded in 2009 and based in Switzerland, OncoEthix is a biotechnology company developing a small portfolio of oncology drugs. The company's main product is OTX015, an orally-administered synthetic small molecule targeting the BET bromodomain proteins 2/3/4.

People
Raphael Wisniewski is a partner at EdRip and worked on the transaction.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Early-stage
• Switzerland
• Andera Partners
• Index Ventures